Session

Thursday
March 21
16:00 - 17:15
Auditorium
Novel systemic therapy for head & neck cancer
Amanda Psyrri, Greece;
Jean-Pascal Machiels, Belgium
Although there have been significant advancements in systemic therapy of recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC), the prognosis for patients remains unfavorable. Antibody-drug conjugates have revolutionized treatment in multiple cancers, both alone and in combination with immunotherapy. Apoptosis-targeting agents have shown promising initial results in the locally advanced setting combined with chemoradiotherapy. Immunotherapy has been shown to extend survival in R/M HNSCC. As a result, novel immunotherapy strategies are presently undergoing clinical evaluation to increase cure rates for head and neck cancer. This session will explore the recent progress in systemic treatment for patients with head and neck cancer.
0050
Symposium
16:00 - 16:25
Recent developments in antibody-drug conjugates (ADC) in the treatment of head & neck cancer
Christophe Le Tourneau , France
16:25 - 16:50
Novel agents targeting apoptosis and other pathways for head & neck cancer
Irene Brana, Spain
16:50 - 17:15
Novel immmunotherapies for head & neck cancer - cell therapy, vaccines and checkpoint inhibitors beyond PD(L)1 and CTLA4
Lisa Licitra, Italy